JBIOJade Biosciences Inc. Common Stock
21.34USD-5.37%Mkt Cap: 1.36B $P/E: —3d ago
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to bl…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
IInsider Monkey | ||
 Assessing Jade Biosciences (JBIO) Valuation After Recent Share Price Weakness And Longer Term Gains Jade Biosciences stock overview following recent trading performance Jade Biosciences (JBIO) has drawn attention after a recent stretch of trading that left the stock down 3.1% on the day and 11.2% over the past week, sharpening interest in its recent gains over the past 3 months and year. See our latest analysis for Jade Biosciences. Despite the weak recent share price returns, with the stock down 21.2% over 30 days, Jade Biosciences still shows strong momentum over longer periods. This is... | ||